Bladder Cancer – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：394頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Bladder Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Bladder Cancer - Pipeline Review, H2 2012', provides an overview of the Bladder Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. 'Bladder Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Bladder Cancer.
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Bladder Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Bladder Cancer - Pipeline Review, H2 2012', provides an overview of the Bladder Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. 'Bladder Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Bladder Cancer.
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Bladder Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Bladder Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Bladder Cancer 13
Bladder Cancer Therapeutics under Development by Companies 15
Bladder Cancer Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Bladder Cancer Therapeutics – Products under Development by Companies 29
Bladder Cancer Therapeutics – Products under Investigation by Universities/Institutes 33
Companies Involved in Bladder Cancer Therapeutics Development 40
Shionogi & Co., Ltd. 40
Sanofi-Aventis 41
Eli Lilly and Company 42
Viralytics Ltd. 43
Bioniche Life Sciences, Inc. 44
Inovio Biomedical Corporation 45
Bavarian Nordic A/S 46
Genta Incorporated 47
MDRNA, Inc. 48
Celgene Corporation 49
Advaxis, Inc. 50
Celldex Therapeutics, Inc. 51
AEterna Zentaris Inc. 52
Cleveland BioLabs, Inc. 53
Oncolytics Biotech Inc. 54
Allos Therapeutics, Inc 55
Oncogenex Pharmaceuticals, Inc. 56
Dendreon Corporation 57
Sanochemia Pharmazeutika AG 58
OncoTherapy Science, Inc. 59
PharmaGap Inc. 60
Quest PharmaTech Inc. 61
Spectrum Pharmaceuticals, Inc. 62
Acceleron Pharma, Inc. 63
Med Discovery SA 64
Altor BioScience Corporation 65
Telormedix SA 66
Gene Signal International SA. 67
Heat Biologics, Inc. 68
MacroGenics, Inc. 69
Stemline Therapeutics, Inc. 70
BioCancell Therapeutics, Inc. 71
AndroScience Corporation 72
Collgard Biopharmaceuticals Ltd. 73
PharmaMar, S.A. 74
TRACON Pharmaceuticals, Inc. 75
Targa Therapeutics Corp. 76
Cytavis Biopharma GmbH 77
EyeGene, Inc. 78
Bladder Cancer – Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Route of Administration 81
Assessment by Molecule Type 84
Drug Profiles 87
AEZS-108 - Drug Profile 87
Icrucumab - Drug Profile 89
Tesetaxel - Drug Profile 90
OGX-427 - Drug Profile 92
Sotatercept - Drug Profile 94
MDRG01 - Drug Profile 96
MDP01 - Drug Profile 97
Abraxane - Drug Profile 98
Urocidin - Drug Profile 100
SL-601 - Drug Profile 102
PVP Hypericin - Drug Profile 103
apaziquone - Drug Profile 104
apaziquone - Drug Profile 106
ALT-801 - Drug Profile 108
TMX-202 - Drug Profile 110
BC-819 - Drug Profile 111
BC-821 - Drug Profile 113
Folotyn - Drug Profile 114
Recombinant Interferon Alfa - Drug Profile 117
SCH 721015 + SCH 209702 - Drug Profile 119
Drug For Bladder Cancer - Drug Profile 120
NY-ESO-1 Peptide Vaccine + BCG Vaccine + Sargramostim - Drug Profile 121
DEPDC1 + MPHOSH1 - Drug Profile 122
B5860N - Drug Profile 123
C2093 - Drug Profile 124
BAY 43-9006 - Drug Profile 125
Piritrexim - Drug Profile 126
Taxotere - Drug Profile 127
Oxaliplatin + Taxotere - Drug Profile 128
5-Fluorouracil - Drug Profile 129
Camptosar - Drug Profile 130
S-288310 - Drug Profile 131
GAP-107B8 - Drug Profile 132
ADXS-HER2 - Drug Profile 134
Cavatak - Drug Profile 135
SL052 - Drug Profile 138
MRNA-046 - Drug Profile 140
CY-503 - Drug Profile 141
Oxaliplatin - Drug Profile 143
tauRNAi - Drug Profile 144
Selenium + Vitamin E - Drug Profile 145
Zalypsis - Drug Profile 146
Sorafenib + Radiation Therapy - Drug Profile 147
GS-101 - Drug Profile 148
Abraxane - Drug Profile 150
Celecoxib - Drug Profile 152
Gemcitabine + Radiation Therapy - Drug Profile 154
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile 155
Abraxane + Lapatinib - Drug Profile 157
Cisplatin + Gemcitabine + Bevacizumab - Drug Profile 159
Vorinostat - Drug Profile 161
Methotrexate + Cisplatin - Drug Profile 163
Gemcitabine + Cisplatin + Amifostine - Drug Profile 164
Fluorouracil + Leucovorin + Gemcitabine + Cisplatin - Drug Profile 166
Herceptin + Paclitaxel - Drug Profile 168
Cisplatin - Drug Profile 170
Gemcitabine + Doxorubicin + Paclitaxel + Carboplatin + Filgrastim - Drug Profile 173
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 176
BAY43-9006 - Drug Profile 177
Paclitaxel + Gemcitabine - Drug Profile 179
Docetaxel + Gemcitabine - Drug Profile 180
Uracil-Tegafur - Drug Profile 181
VEGF Trap - Drug Profile 182
Gemcitabine - Drug Profile 183
E7389 - Drug Profile 185
Sutent - Drug Profile 187
Iressa - Drug Profile 188
Cisplatin + Methotrexate - Drug Profile 190
Docetaxel + Gemcitabine + Neupogen - Drug Profile 191
Methotrexate + Vinblastine + Doxorubicin + Cisplatin - Drug Profile 193
Paclitaxel + Cisplatin + Ifosfamide - Drug Profile 195
Abraxane + Carboplatin + Gemcitabine - Drug Profile 197
Filgrastim + Amifostine - Drug Profile 199
Methotrexate + Vinblastine + Adriamycin + Cisplatin - Drug Profile 200
gemictabine + paclitaxel - Drug Profile 202
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 204
OGX-427 + Docetaxel - Drug Profile 206
TRC-105 - Drug Profile 208
Larotaxel + Cisplatin - Drug Profile 210
Docetaxel + Cisplatin + Gemcitabine + Methotrexate - Drug Profile 212
BCG Vaccine + Iressa - Drug Profile 214
Sutent - Drug Profile 215
Methotrexate + Vinblastine + Doxorubicin + Cisplatin + Gemcitabine - Drug Profile 216
Gemcitabine + CPT-11 - Drug Profile 218
mTOR/PTEN Bladder Cancer Program - Drug Profile 220
Gemcitabine + Cisplatin + Sorafenib - Drug Profile 221
CDX-1401 + Resiquimod - Drug Profile 222
rAd-IFN - Drug Profile 223
Sutent - Drug Profile 225
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 226
Methotrexate + Vinblastine + Doxorubicin + Cisplatin + Filgrastim - Drug Profile 228
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 230
Gemcitabine + Cisplatin + Sunitinib - Drug Profile 232
Gemcitabine + Cisplatin - Drug Profile 233
Tarceva - Drug Profile 234
Gemcitabine + Radiation Therapy - Drug Profile 236
Cyclophosphamide - Drug Profile 238
Cisplatin + Gemcitabine + Temsirolimus - Drug Profile 239
MGAH22 - Drug Profile 241
Cisplatin + Gemcitabine + Sunitinib - Drug Profile 243
SU-011248 - Drug Profile 245
Cetuximab + 5-Fluorouracil + Cisplatin + Radiotherapy - Drug Profile 246
Celecoxib - Drug Profile 248
Gemcitabine + Cisplatin - Drug Profile 249
Reolsyin + Docetaxel - Drug Profile 250
Mitomycin + Hyperthermia Therapy - Drug Profile 252
NY-ESO-1 OLP + Montanide ISA-51 + K-432 - Drug Profile 253
IMC-1121B + Docetaxel - Drug Profile 255
MGAH22 - Drug Profile 257
Carboplatin + Gemcitabine - Drug Profile 258
Carboplatin + Gemcitabine + Vandetanib - Drug Profile 260
MVAC Therapy - Drug Profile 262
BCG Therapy - Drug Profile 264
Cisplatin + Cyclophosphamide + Adriamycin - Drug Profile 265
Cisplatin + Radiation Therapy - Drug Profile 266
Paclitaxel + Hyaluronic Acid - Drug Profile 267
Mitomycin C - Drug Profile 269
Panitumumab + Radiotherapy - Drug Profile 270
5-Fluorouracil + Cisplatin - Drug Profile 271
Cisplatin + Fluorouracil + Radiation Theraphy - Drug Profile 273
Cisplatin + Radiotherapy - Drug Profile 275
Sutent - Drug Profile 277
Carboplatin - Drug Profile 278
Sunitinib - Drug Profile 279
Bevacizumab + Cisplatin + Gemcitabine + Paclitaxel - Drug Profile 280
Cisplatin - Drug Profile 282
GW786034 - Drug Profile 284
Everolimus + Paclitaxel - Drug Profile 285
Gemzar + Cisplatin + Radiation Therapy - Drug Profile 286
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile 287
Gemcitabine + Cisplatin - Drug Profile 289
Cisplatin + Gemcitabine + Sorafenib - Drug Profile 291
Thiotepa - Drug Profile 293
Pirarubicin - Drug Profile 294
Tyverb - Drug Profile 295
Bacillus Calmette-Guerin Vaccine - Drug Profile 296
Gemcitabine Hydrochloride + Doxorubicin + Paclitaxel + Cisplatin + Filgrastim - Drug Profile 298
Doxorubicin + Gemcitabine + Paclitaxel + Cisplatin + Ifosfamide + Filgrastim - Drug Profile 300
Aminophylline + BCG - Drug Profile 302
HS-410 - Drug Profile 303
MGA271 - Drug Profile 304
IMC-D11 + Cisplatin - Drug Profile 305
Pirarubicin - Drug Profile 306
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 307
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 309
TD-1770 - Drug Profile 311
Gemcitabine + Carboplatin + Lenalidomide - Drug Profile 312
DN24-02 - Drug Profile 314
Glycosylated Recombinant Human Interleukin-7 - Drug Profile 315
Neo-Bladder Replacement - Drug Profile 316
Pazopanib + Vinflunine - Drug Profile 317
Gemcitabine + Radiation Therapy - Drug Profile 318
VEGF/rGel - Drug Profile 319
recMAGE-A3 + AS15 - Drug Profile 321
OGX-427 + Gemcitabine + Cisplatin - Drug Profile 322
BO-110 - Drug Profile 324
ONS-1015 - Drug Profile 325
CEL-031 - Drug Profile 327
Zycan - Drug Profile 329
Revercom - Drug Profile 330
Mobilan - Drug Profile 331
ASC-JM.Z1 - Drug Profile 332
V934 - Drug Profile 333
Bladder Cancer Therapeutics – Drug Profile Updates 335
Bladder Cancer Therapeutics – Discontinued Products 362
Bladder Cancer Therapeutics - Dormant Products 364
Bladder Cancer – Product Development Milestones 374
Featured News & Press Releases 374
Appendix 382
Methodology 382
Coverage 382
Secondary Research 382
Primary Research 382
Expert Panel Validation 382
Contact Us 383
Disclaimer 383
List of Tables
Number of Products Under Development for Bladder Cancer, H2 2012 24
Products under Development for Bladder Cancer – Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Development by Companies, H2 2012 (Contd..2) 29
Number of Products under Development by Companies, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 35
Comparative Analysis by Late Stage Development, H2 2012 36
Comparative Analysis by Mid Clinical Stage Development, H2 2012 37
Comparative Analysis by Early Clinical Stage Development, H2 2012 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 39
Products under Development by Companies, H2 2012 40
Products under Development by Companies, H2 2012 (Contd..1) 41
Products under Development by Companies, H2 2012 (Contd..2) 42
Products under Development by Companies, H2 2012 (Contd..3) 43
Products under Investigation by Universities/Institutes, H2 2012 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 50
Shionogi & Co., Ltd., H2 2012 51
Sanofi-Aventis, H2 2012 52
Eli Lilly and Company, H2 2012 53
Viralytics Ltd., H2 2012 54
Bioniche Life Sciences, Inc., H2 2012 55
Inovio Biomedical Corporation, H2 2012 56
Bavarian Nordic A/S, H2 2012 57
Genta Incorporated, H2 2012 58
MDRNA, Inc., H2 2012 59
Celgene Corporation, H2 2012 60
Advaxis, Inc., H2 2012 61
Celldex Therapeutics, Inc., H2 2012 62
AEterna Zentaris Inc., H2 2012 63
Cleveland BioLabs, Inc., H2 2012 64
Oncolytics Biotech Inc., H2 2012 65
Allos Therapeutics, Inc, H2 2012 66
Oncogenex Pharmaceuticals, Inc., H2 2012 67
Dendreon Corporation, H2 2012 68
Sanochemia Pharmazeutika AG, H2 2012 69
OncoTherapy Science, Inc., H2 2012 70
PharmaGap Inc., H2 2012 71
Quest PharmaTech Inc., H2 2012 72
Spectrum Pharmaceuticals, Inc., H2 2012 73
Acceleron Pharma, Inc., H2 2012 74
Med Discovery SA, H2 2012 75
Altor BioScience Corporation, H2 2012 76
Telormedix SA, H2 2012 77
Gene Signal International SA., H2 2012 78
Heat Biologics, Inc., H2 2012 79
MacroGenics, Inc., H2 2012 80
Stemline Therapeutics, Inc., H2 2012 81
BioCancell Therapeutics, Inc., H2 2012 82
AndroScience Corporation, H2 2012 83
Collgard Biopharmaceuticals Ltd., H2 2012 84
PharmaMar, S.A., H2 2012 85
TRACON Pharmaceuticals, Inc., H2 2012 86
Targa Therapeutics Corp., H2 2012 87
Cytavis Biopharma GmbH, H2 2012 88
EyeGene, Inc., H2 2012 89
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Stage and Route of Administration, H2 2012 94
Assessment by Stage and Molecule Type, H2 2012 97
Bladder Cancer Therapeutics – Drug Profile Updates 346
Bladder Cancer Therapeutics – Discontinued Products 373
Bladder Cancer Therapeutics – Discontinued Products (Contd..1) 374
Bladder Cancer Therapeutics – Dormant Products 375
Bladder Cancer Therapeutics – Dormant Products (Contd..1) 376
Bladder Cancer Therapeutics – Dormant Products (Contd..2) 377
Bladder Cancer Therapeutics – Dormant Products (Contd..3) 378
Bladder Cancer Therapeutics – Dormant Products (Contd..4) 379
Bladder Cancer Therapeutics – Dormant Products (Contd..5) 380
Bladder Cancer Therapeutics – Dormant Products (Contd..6) 381
Bladder Cancer Therapeutics – Dormant Products (Contd..7) 382
Bladder Cancer Therapeutics – Dormant Products (Contd..8) 383
Bladder Cancer Therapeutics – Dormant Products (Contd..9) 384
List of Figures
Number of Products under Development for Bladder Cancer, H2 2012 24
Products under Development for Bladder Cancer – Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 31
Late Stage Products, H2 2012 36
Mid Clinical Stage Products, H2 2012 37
Early Clinical Stage Products, H2 2012 38
Discovery and Pre-Clinical Stage Products, H2 2012 39
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Route of Administration, H2 2012 92
Assessment by Stage and Route of Administration, H2 2012 93
Assessment by Molecule Type, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 96
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Bladder Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Bladder Cancer 13
Bladder Cancer Therapeutics under Development by Companies 15
Bladder Cancer Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Bladder Cancer Therapeutics – Products under Development by Companies 29
Bladder Cancer Therapeutics – Products under Investigation by Universities/Institutes 33
Companies Involved in Bladder Cancer Therapeutics Development 40
Shionogi & Co., Ltd. 40
Sanofi-Aventis 41
Eli Lilly and Company 42
Viralytics Ltd. 43
Bioniche Life Sciences, Inc. 44
Inovio Biomedical Corporation 45
Bavarian Nordic A/S 46
Genta Incorporated 47
MDRNA, Inc. 48
Celgene Corporation 49
Advaxis, Inc. 50
Celldex Therapeutics, Inc. 51
AEterna Zentaris Inc. 52
Cleveland BioLabs, Inc. 53
Oncolytics Biotech Inc. 54
Allos Therapeutics, Inc 55
Oncogenex Pharmaceuticals, Inc. 56
Dendreon Corporation 57
Sanochemia Pharmazeutika AG 58
OncoTherapy Science, Inc. 59
PharmaGap Inc. 60
Quest PharmaTech Inc. 61
Spectrum Pharmaceuticals, Inc. 62
Acceleron Pharma, Inc. 63
Med Discovery SA 64
Altor BioScience Corporation 65
Telormedix SA 66
Gene Signal International SA. 67
Heat Biologics, Inc. 68
MacroGenics, Inc. 69
Stemline Therapeutics, Inc. 70
BioCancell Therapeutics, Inc. 71
AndroScience Corporation 72
Collgard Biopharmaceuticals Ltd. 73
PharmaMar, S.A. 74
TRACON Pharmaceuticals, Inc. 75
Targa Therapeutics Corp. 76
Cytavis Biopharma GmbH 77
EyeGene, Inc. 78
Bladder Cancer – Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Route of Administration 81
Assessment by Molecule Type 84
Drug Profiles 87
AEZS-108 - Drug Profile 87
Icrucumab - Drug Profile 89
Tesetaxel - Drug Profile 90
OGX-427 - Drug Profile 92
Sotatercept - Drug Profile 94
MDRG01 - Drug Profile 96
MDP01 - Drug Profile 97
Abraxane - Drug Profile 98
Urocidin - Drug Profile 100
SL-601 - Drug Profile 102
PVP Hypericin - Drug Profile 103
apaziquone - Drug Profile 104
apaziquone - Drug Profile 106
ALT-801 - Drug Profile 108
TMX-202 - Drug Profile 110
BC-819 - Drug Profile 111
BC-821 - Drug Profile 113
Folotyn - Drug Profile 114
Recombinant Interferon Alfa - Drug Profile 117
SCH 721015 + SCH 209702 - Drug Profile 119
Drug For Bladder Cancer - Drug Profile 120
NY-ESO-1 Peptide Vaccine + BCG Vaccine + Sargramostim - Drug Profile 121
DEPDC1 + MPHOSH1 - Drug Profile 122
B5860N - Drug Profile 123
C2093 - Drug Profile 124
BAY 43-9006 - Drug Profile 125
Piritrexim - Drug Profile 126
Taxotere - Drug Profile 127
Oxaliplatin + Taxotere - Drug Profile 128
5-Fluorouracil - Drug Profile 129
Camptosar - Drug Profile 130
S-288310 - Drug Profile 131
GAP-107B8 - Drug Profile 132
ADXS-HER2 - Drug Profile 134
Cavatak - Drug Profile 135
SL052 - Drug Profile 138
MRNA-046 - Drug Profile 140
CY-503 - Drug Profile 141
Oxaliplatin - Drug Profile 143
tauRNAi - Drug Profile 144
Selenium + Vitamin E - Drug Profile 145
Zalypsis - Drug Profile 146
Sorafenib + Radiation Therapy - Drug Profile 147
GS-101 - Drug Profile 148
Abraxane - Drug Profile 150
Celecoxib - Drug Profile 152
Gemcitabine + Radiation Therapy - Drug Profile 154
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile 155
Abraxane + Lapatinib - Drug Profile 157
Cisplatin + Gemcitabine + Bevacizumab - Drug Profile 159
Vorinostat - Drug Profile 161
Methotrexate + Cisplatin - Drug Profile 163
Gemcitabine + Cisplatin + Amifostine - Drug Profile 164
Fluorouracil + Leucovorin + Gemcitabine + Cisplatin - Drug Profile 166
Herceptin + Paclitaxel - Drug Profile 168
Cisplatin - Drug Profile 170
Gemcitabine + Doxorubicin + Paclitaxel + Carboplatin + Filgrastim - Drug Profile 173
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 176
BAY43-9006 - Drug Profile 177
Paclitaxel + Gemcitabine - Drug Profile 179
Docetaxel + Gemcitabine - Drug Profile 180
Uracil-Tegafur - Drug Profile 181
VEGF Trap - Drug Profile 182
Gemcitabine - Drug Profile 183
E7389 - Drug Profile 185
Sutent - Drug Profile 187
Iressa - Drug Profile 188
Cisplatin + Methotrexate - Drug Profile 190
Docetaxel + Gemcitabine + Neupogen - Drug Profile 191
Methotrexate + Vinblastine + Doxorubicin + Cisplatin - Drug Profile 193
Paclitaxel + Cisplatin + Ifosfamide - Drug Profile 195
Abraxane + Carboplatin + Gemcitabine - Drug Profile 197
Filgrastim + Amifostine - Drug Profile 199
Methotrexate + Vinblastine + Adriamycin + Cisplatin - Drug Profile 200
gemictabine + paclitaxel - Drug Profile 202
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 204
OGX-427 + Docetaxel - Drug Profile 206
TRC-105 - Drug Profile 208
Larotaxel + Cisplatin - Drug Profile 210
Docetaxel + Cisplatin + Gemcitabine + Methotrexate - Drug Profile 212
BCG Vaccine + Iressa - Drug Profile 214
Sutent - Drug Profile 215
Methotrexate + Vinblastine + Doxorubicin + Cisplatin + Gemcitabine - Drug Profile 216
Gemcitabine + CPT-11 - Drug Profile 218
mTOR/PTEN Bladder Cancer Program - Drug Profile 220
Gemcitabine + Cisplatin + Sorafenib - Drug Profile 221
CDX-1401 + Resiquimod - Drug Profile 222
rAd-IFN - Drug Profile 223
Sutent - Drug Profile 225
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 226
Methotrexate + Vinblastine + Doxorubicin + Cisplatin + Filgrastim - Drug Profile 228
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 230
Gemcitabine + Cisplatin + Sunitinib - Drug Profile 232
Gemcitabine + Cisplatin - Drug Profile 233
Tarceva - Drug Profile 234
Gemcitabine + Radiation Therapy - Drug Profile 236
Cyclophosphamide - Drug Profile 238
Cisplatin + Gemcitabine + Temsirolimus - Drug Profile 239
MGAH22 - Drug Profile 241
Cisplatin + Gemcitabine + Sunitinib - Drug Profile 243
SU-011248 - Drug Profile 245
Cetuximab + 5-Fluorouracil + Cisplatin + Radiotherapy - Drug Profile 246
Celecoxib - Drug Profile 248
Gemcitabine + Cisplatin - Drug Profile 249
Reolsyin + Docetaxel - Drug Profile 250
Mitomycin + Hyperthermia Therapy - Drug Profile 252
NY-ESO-1 OLP + Montanide ISA-51 + K-432 - Drug Profile 253
IMC-1121B + Docetaxel - Drug Profile 255
MGAH22 - Drug Profile 257
Carboplatin + Gemcitabine - Drug Profile 258
Carboplatin + Gemcitabine + Vandetanib - Drug Profile 260
MVAC Therapy - Drug Profile 262
BCG Therapy - Drug Profile 264
Cisplatin + Cyclophosphamide + Adriamycin - Drug Profile 265
Cisplatin + Radiation Therapy - Drug Profile 266
Paclitaxel + Hyaluronic Acid - Drug Profile 267
Mitomycin C - Drug Profile 269
Panitumumab + Radiotherapy - Drug Profile 270
5-Fluorouracil + Cisplatin - Drug Profile 271
Cisplatin + Fluorouracil + Radiation Theraphy - Drug Profile 273
Cisplatin + Radiotherapy - Drug Profile 275
Sutent - Drug Profile 277
Carboplatin - Drug Profile 278
Sunitinib - Drug Profile 279
Bevacizumab + Cisplatin + Gemcitabine + Paclitaxel - Drug Profile 280
Cisplatin - Drug Profile 282
GW786034 - Drug Profile 284
Everolimus + Paclitaxel - Drug Profile 285
Gemzar + Cisplatin + Radiation Therapy - Drug Profile 286
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile 287
Gemcitabine + Cisplatin - Drug Profile 289
Cisplatin + Gemcitabine + Sorafenib - Drug Profile 291
Thiotepa - Drug Profile 293
Pirarubicin - Drug Profile 294
Tyverb - Drug Profile 295
Bacillus Calmette-Guerin Vaccine - Drug Profile 296
Gemcitabine Hydrochloride + Doxorubicin + Paclitaxel + Cisplatin + Filgrastim - Drug Profile 298
Doxorubicin + Gemcitabine + Paclitaxel + Cisplatin + Ifosfamide + Filgrastim - Drug Profile 300
Aminophylline + BCG - Drug Profile 302
HS-410 - Drug Profile 303
MGA271 - Drug Profile 304
IMC-D11 + Cisplatin - Drug Profile 305
Pirarubicin - Drug Profile 306
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 307
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 309
TD-1770 - Drug Profile 311
Gemcitabine + Carboplatin + Lenalidomide - Drug Profile 312
DN24-02 - Drug Profile 314
Glycosylated Recombinant Human Interleukin-7 - Drug Profile 315
Neo-Bladder Replacement - Drug Profile 316
Pazopanib + Vinflunine - Drug Profile 317
Gemcitabine + Radiation Therapy - Drug Profile 318
VEGF/rGel - Drug Profile 319
recMAGE-A3 + AS15 - Drug Profile 321
OGX-427 + Gemcitabine + Cisplatin - Drug Profile 322
BO-110 - Drug Profile 324
ONS-1015 - Drug Profile 325
CEL-031 - Drug Profile 327
Zycan - Drug Profile 329
Revercom - Drug Profile 330
Mobilan - Drug Profile 331
ASC-JM.Z1 - Drug Profile 332
V934 - Drug Profile 333
Bladder Cancer Therapeutics – Drug Profile Updates 335
Bladder Cancer Therapeutics – Discontinued Products 362
Bladder Cancer Therapeutics - Dormant Products 364
Bladder Cancer – Product Development Milestones 374
Featured News & Press Releases 374
Appendix 382
Methodology 382
Coverage 382
Secondary Research 382
Primary Research 382
Expert Panel Validation 382
Contact Us 383
Disclaimer 383
List of Tables
Number of Products Under Development for Bladder Cancer, H2 2012 24
Products under Development for Bladder Cancer – Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Development by Companies, H2 2012 (Contd..2) 29
Number of Products under Development by Companies, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 35
Comparative Analysis by Late Stage Development, H2 2012 36
Comparative Analysis by Mid Clinical Stage Development, H2 2012 37
Comparative Analysis by Early Clinical Stage Development, H2 2012 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 39
Products under Development by Companies, H2 2012 40
Products under Development by Companies, H2 2012 (Contd..1) 41
Products under Development by Companies, H2 2012 (Contd..2) 42
Products under Development by Companies, H2 2012 (Contd..3) 43
Products under Investigation by Universities/Institutes, H2 2012 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 50
Shionogi & Co., Ltd., H2 2012 51
Sanofi-Aventis, H2 2012 52
Eli Lilly and Company, H2 2012 53
Viralytics Ltd., H2 2012 54
Bioniche Life Sciences, Inc., H2 2012 55
Inovio Biomedical Corporation, H2 2012 56
Bavarian Nordic A/S, H2 2012 57
Genta Incorporated, H2 2012 58
MDRNA, Inc., H2 2012 59
Celgene Corporation, H2 2012 60
Advaxis, Inc., H2 2012 61
Celldex Therapeutics, Inc., H2 2012 62
AEterna Zentaris Inc., H2 2012 63
Cleveland BioLabs, Inc., H2 2012 64
Oncolytics Biotech Inc., H2 2012 65
Allos Therapeutics, Inc, H2 2012 66
Oncogenex Pharmaceuticals, Inc., H2 2012 67
Dendreon Corporation, H2 2012 68
Sanochemia Pharmazeutika AG, H2 2012 69
OncoTherapy Science, Inc., H2 2012 70
PharmaGap Inc., H2 2012 71
Quest PharmaTech Inc., H2 2012 72
Spectrum Pharmaceuticals, Inc., H2 2012 73
Acceleron Pharma, Inc., H2 2012 74
Med Discovery SA, H2 2012 75
Altor BioScience Corporation, H2 2012 76
Telormedix SA, H2 2012 77
Gene Signal International SA., H2 2012 78
Heat Biologics, Inc., H2 2012 79
MacroGenics, Inc., H2 2012 80
Stemline Therapeutics, Inc., H2 2012 81
BioCancell Therapeutics, Inc., H2 2012 82
AndroScience Corporation, H2 2012 83
Collgard Biopharmaceuticals Ltd., H2 2012 84
PharmaMar, S.A., H2 2012 85
TRACON Pharmaceuticals, Inc., H2 2012 86
Targa Therapeutics Corp., H2 2012 87
Cytavis Biopharma GmbH, H2 2012 88
EyeGene, Inc., H2 2012 89
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Stage and Route of Administration, H2 2012 94
Assessment by Stage and Molecule Type, H2 2012 97
Bladder Cancer Therapeutics – Drug Profile Updates 346
Bladder Cancer Therapeutics – Discontinued Products 373
Bladder Cancer Therapeutics – Discontinued Products (Contd..1) 374
Bladder Cancer Therapeutics – Dormant Products 375
Bladder Cancer Therapeutics – Dormant Products (Contd..1) 376
Bladder Cancer Therapeutics – Dormant Products (Contd..2) 377
Bladder Cancer Therapeutics – Dormant Products (Contd..3) 378
Bladder Cancer Therapeutics – Dormant Products (Contd..4) 379
Bladder Cancer Therapeutics – Dormant Products (Contd..5) 380
Bladder Cancer Therapeutics – Dormant Products (Contd..6) 381
Bladder Cancer Therapeutics – Dormant Products (Contd..7) 382
Bladder Cancer Therapeutics – Dormant Products (Contd..8) 383
Bladder Cancer Therapeutics – Dormant Products (Contd..9) 384
List of Figures
Number of Products under Development for Bladder Cancer, H2 2012 24
Products under Development for Bladder Cancer – Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 31
Late Stage Products, H2 2012 36
Mid Clinical Stage Products, H2 2012 37
Early Clinical Stage Products, H2 2012 38
Discovery and Pre-Clinical Stage Products, H2 2012 39
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Route of Administration, H2 2012 92
Assessment by Stage and Route of Administration, H2 2012 93
Assessment by Molecule Type, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 96
